The administration of αPTX3i (10 mg/kg/week) significantly recovered body weight loss (Figure 7A), prolonged overall animal survival (Figure 7B), reduced lung and plasma Ptx3 (Figure 7C), reduced the severity of pulmonary fibrosis as examined by H&E staining, Sirius red staining and Masson's staining (Figure 7D), decreased the extent of pulmonary damage (Figure 7E) and content of hydroxyproline (Figure 7F) and improved pulmonary function (Figure 7G) compared to pirfenidone (100 mg/kg/day) and nintedanib (60 mg/kg/day) in bleomycin‐exposed mice. The gene discussed is PTX3; the disease is pulmonary fibrosis.